Chris Wealth Management

Search This Blog

Motilal Oswal sees 28% upside in Glenmark Pharma

Posted by Able on July 11, 2025

Get link
Facebook
X
Pinterest
Email
Other Apps

Motilal Oswal has reiterated a “buy” rating on Glenmark Pharmaceuticals with a raised target price of Rs 2,430, implying a 28% upside from the current market price of Rs 1,904.

Get link
Facebook
X
Pinterest
Email
Other Apps

Comments

Stock Market LIVE Updates: Hong Kong stocks notch 9-day winning streak in longest rally since 2018

Hong Kong stocks extended their rally on Friday, supported by ongoing positive market sentiment fueled by China's increased economic stimulus measures. The Hang Seng Index surged by 1.5%, marking its ninth consecutive day of gains, the longest winning streak since January 2018. Hong Kong-listed Chinese tech giants also saw continued gains, closing 2.7% higher.

Jiraaf launches India’s first Bond Analyser to decode fixed-income investing

Jiraaf launches Bond Analyser to simplify bond investing for retail investors. Tool compares yields by rating, tenure, and issuer using public data. Aims to close the research gap in India’s growing fixed-income market. Future updates may include scenario modeling and structured debt analysis.

After challenging FY25, Apollo Tyres looking ahead with cautious optimism

After enduring a challenging year in FY25, Apollo Tyres is looking forward with optimism to the opportunities as it sharpens execution and investment in future-ready capabilities, according to company Chairman Onkar Kanwar. In his address to shareholders in the company's annual report for 2024-25, Kanwar said the company has already put in motion key initiatives to drive performance, including expanding passenger car radial (PCR) capacities at its Hungary and Andhra Pradesh plants, with an estimated capex of Rs 1,500 crore. Reflecting on FY25, he said, the company's commitment to the core principles of "profitable growth, market expansion and a relentless focus on cost and quality" remained constant.

Motilal Oswal sees 28% upside in Glenmark Pharma

Comments

Post a Comment